Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cumberland Pharmaceuticals Inc (CPIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014391
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a pharmaceutical company which develops and commercializes branded prescription products. The company’s product portfolio includes acetylcysteine, ibuprofen, lactulose, conivaptan, amifostine and ifetroban. It provides prescription products for hospitals, acute cares, unmet medical needs and gastroenterology. Cumberland Pharma’s acetylcysteine is used for the prevention of liver damage resulting from acetaminophen overdose. The company works in partnership Phebra Pty Ltd, Teligent Pharmaceuticals Inc, DB Pharm Korea Co Ltd, Sandor Medicaids Pvt. Ltd for commercialization of the products internationally. It markets the branded products through a channel of network distributors in the US and abroad. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.

Cumberland Pharmaceuticals Inc (CPIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Partnerships 17
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Licensing Agreements 24
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Equity Offering 30
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc – Key Competitors 32
Cumberland Pharmaceuticals Inc – Key Employees 33
Cumberland Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter 35
Aug 08, 2017: Cumberland Pharmaceuticals Reports Double Digit Revenue Growth for the Fourth Consecutive Quarter 37
May 15, 2017: Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017 39
Mar 07, 2017: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results 41
Nov 01, 2016: Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results 43
Aug 02, 2016: Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results 45
May 10, 2016: Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results 47
Mar 03, 2016: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results 49
Corporate Communications 50
Jan 16, 2017: Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors 50
Jun 10, 2016: Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors 51
Product Approvals 52
Apr 27, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Vasculan For Systemic Sclerosis 52
Clinical Trials 53
Sep 14, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Portaban For Portal Hypertension 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc, Key Competitors 32
Cumberland Pharmaceuticals Inc, Key Employees 33
Cumberland Pharmaceuticals Inc, Subsidiaries 34

★海外企業調査レポート[Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …
  • Medicines for Malaria Venture-製薬・医療分野:企業M&A・提携分析
    Summary Medicines for Malaria Venture (MMV) is a drug development and manufacturing company that discovers, develops and delivers anti malarial drugs. The company offers products that provide efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • Aerostar S.A.:企業の戦略・SWOT・財務分析
    Aerostar S.A. - Strategy, SWOT and Corporate Finance Report Summary Aerostar S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Proteon Therapeutics Inc (PRTO):製薬・医療:M&Aディール及び事業提携情報
    Summary Proteon Therapeutics Inc (Proteon Therapeutics) is a late-stage biopharmaceutical company that develops pharmaceutical products for the treatment of renal and vascular diseases. The company develops investigational therapies to treat hemodialysis and peripheral artery disease patients. Its p …
  • Augmenix Inc-医療機器分野:企業M&A・提携分析
    Summary Augmenix Inc (Augmenix) is a medical device company that develops space-filling hydrogels for radiation oncology and cancer surgery indications. The company offers products such as hydrogel products, space OAR systems, absorbable tissue marker, and trace-IT hydrogel products. Its TraceIT hyd …
  • China Shineway Pharmaceutical Group Ltd (2877):企業の財務・戦略的SWOT分析
    Summary China Shineway Pharmaceutical Group Ltd (China Shineway) is a pharmaceutical company that offers development, manufacture and sales of Chinese medicines. The company’s products comprise shenmai injection, qingkailing injection, huangqi injection, shuxiening injection, wufu xinnaoqing soft ca …
  • Athena Investments AS (ATHENA):企業の財務・戦略的SWOT分析
    Athena Investments AS (ATHENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • AIA Insurance Lanka Plc (CTCE.N0000):企業の財務・戦略的SWOT分析
    AIA Insurance Lanka Plc (CTCE.N0000) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Innospec Inc. (IOSP):石油・ガス:M&Aディール及び事業提携情報
    Summary Innospec Inc (Innospec) is a provider of specialty chemicals. It blends, manufactures and supplies fuel additives and other specialty chemicals. Innospec’s product portfolio includes stabilizers, detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, conductivity improve …
  • MedicPen AB (MPEN):医療機器:M&Aディール及び事業提携情報
    Summary MedicPen AB (MedicPen) is a drug development company that manufactures, develops, and markets patented products. The company’s products include Medimi Pro and Medimi Smart. It also provides Medimi – MedicPen’s system for medication assistance. MedicPen offers automatic filling units for home …
  • Colt Group Ltd:企業の戦略的SWOT分析
    Colt Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • MSL Solutions Limited (MPW):企業の財務・戦略的SWOT分析
    MSL Solutions Limited (MPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Ricoh Company, Ltd. (7752):企業の財務・戦略的SWOT分析
    Ricoh Company, Ltd. (7752) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Cadila Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cadila Pharmaceuticals Ltd (Cadila Pharmaceuticals) is a pharmaceutical company that develops, manufactures and distributes pharmaceutical products. The company's products include active pharmaceutical ingredients (API) and pharmaceutical formulations. Its business includes contract research …
  • MagForce AG (MF6):企業の財務・戦略的SWOT分析
    Summary MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas …
  • Astrazeneca Pharma India Ltd (ASTRAZEN):企業の財務・戦略的SWOT分析
    Summary AstraZeneca Pharma India Ltd (AstraZeneca), a subsidiary of AstraZeneca Plc, is a biopharmaceutical company. It discovers, develops, supplies and commercializes medicines. The company’s product portfolio include Forxiga, Imdur, Crestor, Tagrisso, Lynparza, Betaloc, Symbicort, budesonide, for …
  • Renesola Ltd (SOL):電力:M&Aディール及び事業提携情報
    Summary Renesola Ltd (ReneSola) is a solar project developer and operator of energy efficient products that manufactures polysilicon, monocrystalline and multi crystalline solar wafers; and solar photovoltaic cells and modules. It also develops, builds and sells solar power projects across Europe, N …
  • Analog Modules, Inc.:企業の戦略・SWOT・財務分析
    Analog Modules, Inc. - Strategy, SWOT and Corporate Finance Report Summary Analog Modules, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Abraaj Group-エネルギー分野:企業M&A・提携分析
    Summary The Abraaj Group (Abraaj) is a financial service provider that offers private equity, investment and credit strategies for real estate operations. The company helps companies in their operational improvements, management incentives, optimization of capital structure and the use of leverage. …
  • Carisma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carisma Therapeutics Inc (Carisma Therapeutics), formerly CARMA Therapeutics LLC, is a biotechnology company with focus on the discovery and development of macrophage-based immunotherapeutics for the treatment of cancer. The company exploits its proprietary CAR-macrophage platform to provide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆